Clinical Trial

Impact of Breast Milk on the Infectivity and Transmission of Different Viruses "BREASTMILKVIR"

Study acronym: BREASTMILKVIR
Recruiting
View on ClinicalTrials.gov →
Summary
Exclusive breastfeeding during the first six months of life and continued breastfeeding for at least 24 months constitute the optimal feeding method for infants and young children. However, breast milk and breastfeeding can be significant pathways for the transmission of certain viruses. The objective of this study is to examine the influence of human breast milk and its composition on viral infectivity and viral transmission of the HTLV-1 virus and arboviruses such as Zika virus, yellow fever, dengue, and tick-borne encephalitis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-16.
Status change: Not Yet Recruiting → Recruiting 2025-12-08
Trial Details
NCT Number NCT06738563
Lead Sponsor Institut Pasteur
Conditions Breastmilk Collection
Enrollment 75 participants
Start Date 2025-09-10
Primary Completion 2028-09 (estimated)
Study Completion 2030-09 (estimated)
Updated on ClinicalTrials.gov 2025-12-15